Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives October 9, 2026 8:00 AM EDT
Company Participants
Christopher Stevo – Senior Vice President of Investor Relations & Competitive Intelligence
Richard Francis – President, CEO & Director
Eric Hughes – Executive VP of Global R&D and Chief Medical Officer
Christine Fox – Executive VP of US Commercial & Head of Innovative Franchise
Conference Call Participants
Joseph Thome – TD Cowen, Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Louise Chen – Scotiabank Global Banking and Markets, Research Division
Les Sulewski
David Amsellem – Piper Sandler & Co., Research Division
Jason Gerberry – BofA Securities, Research Division
Di Zhao – UBS Investment Bank, Research Division
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Presentation
Operator
Hello, and welcome to the WELTRUZA approval conference call. My name is Alex. I’ll be coordinating today’s call. [Operator Instructions] I’ll now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead.
Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence
Thank you, Alex. Good morning, and good afternoon, everyone. Thank you for joining us on short notice to discuss the U.S. FDA approval of WELTRUZA, olanzapine LAI. The materials are posted to the website this morning, and the press release is also on our website. And before I turn the call over to Richard Francis, I’d like to remind everyone that we’ll be making forward-looking statements on the call.
The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-K and 10-Q filed with the SEC. Any statements that we
